{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:13:44Z","timestamp":1791220424690,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.2353\/jmoldx.2008.080052","type":"journal-article","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T20:25:31Z","timestamp":1222979131000},"page":"527-536","source":"Crossref","is-referenced-by-count":39,"title":["Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists"],"prefix":"10.1016","volume":"10","author":[{"given":"Antonino","family":"Carbone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Truini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Mangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Perin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Testi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verderio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2353\/jmoldx.2008.080052_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.2353\/jmoldx.2008.080052_bib2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc1360","article-title":"The discovery of receptor tyrosine kinases: target for cancer therapy","volume":"4","author":"Gschwind","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.2353\/jmoldx.2008.080052_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000134507","article-title":"Assignment of c-erb-B2 avian erythroblastic leukemic viral oncogene homolog 2 (ERBB2) to human chromosome band 17121.1 by in situ hybridization","volume":"76","author":"Muleris","year":"1997","journal-title":"Cytogenet Cell Genet"},{"key":"10.2353\/jmoldx.2008.080052_bib4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"10.2353\/jmoldx.2008.080052_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.2353\/jmoldx.2008.080052_bib6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1126\/science.3012781","article-title":"The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"key":"10.2353\/jmoldx.2008.080052_bib7","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","article-title":"HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas","volume":"15","author":"Press","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2008.080052_bib8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.1992.10.7.1049","article-title":"Prognostic importance of c-erbB-2 expression in breast cancer","volume":"10","author":"Gusterson","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2008.080052_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ijc.2910490504","article-title":"Association of c-erbB-2 protein expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer","volume":"49","author":"Kallioniemi","year":"1991","journal-title":"Int J Cancer"},{"key":"10.2353\/jmoldx.2008.080052_bib10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2008.080052_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized controlled trial","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2008.080052_bib12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.2353\/jmoldx.2008.080052_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/modpathol.3800774","article-title":"Standardization of HER2 testing: results of an international proficiency-testing ring study","volume":"20","author":"Dowsett","year":"2007","journal-title":"Mod Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib14","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/jnci\/94.11.852","article-title":"Real-world performance of HER2 testing \u2013 National Surgical Adjuvant Breast and Bowel Project experience","volume":"94","author":"Paik","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.2353\/jmoldx.2008.080052_bib15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/94.11.855","article-title":"Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831","volume":"94","author":"Roche","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.2353\/jmoldx.2008.080052_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2008.080052_bib17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)64785-2","article-title":"Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2\/neu oncogene amplification in archival breast cancer samples","volume":"157","author":"Tanner","year":"2000","journal-title":"Am J Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib18","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0002-9440(10)65727-6","article-title":"Subtracted, unique-sequence, in situ hybridization: experimental and diagnostic applications","volume":"153","author":"Davison","year":"1998","journal-title":"Am J Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/modpathol.3880582","article-title":"Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma","volume":"15","author":"Zhao","year":"2002","journal-title":"Mod Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10735-004-2191-9","article-title":"Novel bright field molecular morphology methods for detection of HER2 gene amplification","volume":"35","author":"Tubbs","year":"2004","journal-title":"J Mol Histol"},{"key":"10.2353\/jmoldx.2008.080052_bib21","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/01.pas.0000172294.67409.4f","article-title":"Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast","volume":"29","author":"Downs-Kelly","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib22","series-title":"Statistical methods for rates and proportions","first-page":"212","author":"Fleiss","year":"1981"},{"key":"10.2353\/jmoldx.2008.080052_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00428-007-0424-5","article-title":"Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists","volume":"451","author":"Dietel","year":"2007","journal-title":"Virchows Arch"},{"key":"10.2353\/jmoldx.2008.080052_bib24","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jcp.2006.043356","article-title":"Chromogenic in-situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer","volume":"60","author":"Di Palma","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1309\/C4PEBGB9LN830TVL","article-title":"Chromogenic in situ hybridization for the detection of HER-2\/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?","volume":"123","author":"Bhargava","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib26","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-0428-03","article-title":"Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization","volume":"10","author":"Isola","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.2353\/jmoldx.2008.080052_bib27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.breast.2007.05.008","article-title":"Comparative evaluation of non-informative HER-2 immunoreactions (2(+)) in breast carcinomas with FISH","volume":"16","author":"Kostopoulou","year":"2007","journal-title":"CISH and QRT-PCR Breast"},{"key":"10.2353\/jmoldx.2008.080052_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/modpathol.3800555","article-title":"Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm","volume":"19","author":"Hanna","year":"2006","journal-title":"Mod Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.breast.2005.09.008","article-title":"HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer \u2013 A study of two hundred cases","volume":"15","author":"S\u00e1ez","year":"2006","journal-title":"Breast"},{"key":"10.2353\/jmoldx.2008.080052_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-007-9887-y","article-title":"New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up","author":"Jensen","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.2353\/jmoldx.2008.080052_bib31","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","article-title":"Assessment of methods for tissue-based detection of the HER-2\/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry","volume":"18","author":"Pauletti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.2353\/jmoldx.2008.080052_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/modpathol.3880007","article-title":"Determination of HER-2\/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization","volume":"13","author":"Jimenez","year":"2000","journal-title":"Mod Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib33","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/modpathol.3880228","article-title":"Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2\/neu) gene status in breast carcinoma","volume":"13","author":"Couturier","year":"2000","journal-title":"Mod Pathol"},{"key":"10.2353\/jmoldx.2008.080052_bib34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4065\/77.2.148","article-title":"HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization","volume":"77","author":"Perez","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.2353\/jmoldx.2008.080052_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/PAI.0b013e31802ced25","article-title":"A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility","volume":"15","author":"Powell","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157810601961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157810601961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T07:34:08Z","timestamp":1557819248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157810601961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S1525157810601961"],"URL":"https:\/\/doi.org\/10.2353\/jmoldx.2008.080052","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}